Literature DB >> 11154271

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.

X Zhang1, R Subrahmanyam, R Wong, A W Gross, R Ren.   

Abstract

Bcr-Abl, a fusion protein generated by t(9;22)(q34;q11) translocation, plays a critical role in the pathogenesis of chronic myelogenous leukemia (CML). It has been shown that Bcr-Abl contains multiple functional domains and motifs and can disrupt regulation of many signaling pathways and cellular functions. However, the role of specific domains and motifs of Bcr-Abl or of specific signaling pathways in the complex in vivo pathogenesis of CML is not completely known. We have previously shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces a myeloproliferative disorder (MPD) in mice resembling human CML. We have also shown that the Abl kinase activity within Bcr-Abl is essential for Bcr-Abl leukemogenesis, yet activation of the Abl kinase without Bcr sequences is not sufficient to induce MPD in mice. In this study we investigated the role of Bcr sequences within Bcr-Abl in inducing MPD using this murine model for CML. We found that the NH(2)-terminal coiled-coil (CC) domain was both essential and sufficient, even though not efficient, to activate Abl to induce an MPD in mice. Interestingly, deletion of the Src homology 3 domain complemented the deficiencies of the CC-deleted Bcr-Abl in inducing MPD in mice. We further demonstrated that the Grb2 binding site at Y177 played an important role in efficient induction of MPD. These studies directly demonstrated the important roles of Bcr sequences in induction of MPD by Bcr-Abl.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154271      PMCID: PMC86675          DOI: 10.1128/MCB.21.3.840-853.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

1.  Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.

Authors:  A Goga; J McLaughlin; D E Afar; D C Saffran; O N Witte
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

2.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.

Authors:  D Cortez; L Kadlec; A M Pendergast
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

3.  The novel activation of ABL by fusion to an ets-related gene, TEL.

Authors:  P Papadopoulos; S A Ridge; C A Boucher; C Stocking; L M Wiedemann
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

4.  Non-globular domains in protein sequences: automated segmentation using complexity measures.

Authors:  J C Wootton
Journal:  Comput Chem       Date:  1994-09

5.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.

Authors:  A M Pendergast; L A Quilliam; L D Cripe; C H Bassing; Z Dai; N Li; A Batzer; K M Rabun; C J Der; J Schlessinger
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

6.  Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.

Authors:  B J Mayer; D Baltimore
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

7.  Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.

Authors:  R Ren; Z S Ye; D Baltimore
Journal:  Genes Dev       Date:  1994-04-01       Impact factor: 11.361

8.  BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.

Authors:  J Liu; M Campbell; J Q Guo; D Lu; Y M Xian; B S Andersson; R B Arlinghaus
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

9.  Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.

Authors:  H Honda; T Fujii; M Takatoku; H Mano; O N Witte; Y Yazaki; H Hirai
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

10.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.

Authors:  J R McWhirter; D L Galasso; J Y Wang
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

View more
  34 in total

1.  The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain.

Authors:  Andrew S Dixon; Carol S Lim
Journal:  Biotechniques       Date:  2010-07       Impact factor: 1.993

2.  The MORC family: new epigenetic regulators of transcription and DNA damage response.

Authors:  Da-Qiang Li; Sujit S Nair; Rakesh Kumar
Journal:  Epigenetics       Date:  2013-05-17       Impact factor: 4.528

3.  Disruption of Bcr-Abl coiled coil oligomerization by design.

Authors:  Andrew S Dixon; Scott S Pendley; Benjamin J Bruno; David W Woessner; Adrian A Shimpi; Thomas E Cheatham; Carol S Lim
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

Review 4.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

Review 5.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

6.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

7.  MORC3, a Component of PML Nuclear Bodies, Has a Role in Restricting Herpes Simplex Virus 1 and Human Cytomegalovirus.

Authors:  Elizabeth Sloan; Anne Orr; Roger D Everett
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

8.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.

Authors:  David W Woessner; Carol S Lim
Journal:  Mol Pharm       Date:  2012-12-18       Impact factor: 4.939

10.  Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.

Authors:  Ji Wu; Feng Meng; Henry Lu; Ling Kong; William Bornmann; Zhenghong Peng; Moshe Talpaz; Nicholas J Donato
Journal:  Blood       Date:  2008-01-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.